(Q34109516)

31 July 2017

title

Aliskiren displays long-lasting interactions with human renin (English)

1 reference

31 July 2017

Thomas Gossas

1

1 reference

31 July 2017

Lotta Vrang

2

1 reference

31 July 2017

Ian Henderson

3

1 reference

31 July 2017

Susanne Sedig

4

1 reference

31 July 2017

Christer Sahlberg

5

1 reference

31 July 2017

Erik Lindström

6

1 reference

31 July 2017

U Helena Danielson

7

1 reference

31 July 2017

publication date

23 December 2011

1 reference

Naunyn-Schmiedeberg's Archives of Pharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

385

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

219-224

1 reference

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Drug-target residence time and its implications for lead optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Ro 42-5892 is a potent orally active renin inhibitor in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Is there a future for renin inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Aliskiren accumulates in Renin secretory granules and binds plasma prorenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Pharmacologic target-mediated drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

The preparation, purification, and amino acid sequence of a polypeptide renin substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Residence time of receptor-ligand complexes and its effect on biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Slow antagonist dissociation and long-lasting in vivo receptor protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Structure-based design of aliskiren, a novel orally effective renin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-011-0718-7

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

21 January 2018

1 reference

12 December 2020

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

12 December 2020

Characterization of recombinant human prorenin and renin.

1 reference

12 December 2020

Time dependency of the antihypertensive efficacy of the new renin inhibitor Ro 42-5892

1 reference

12 December 2020

Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension.

1 reference

12 December 2020

Importance of blood pressure control over a 24-hour period

1 reference

12 December 2020

10.1007/S00210-011-0718-7

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1042941791

0 references

1 reference